Andrew J. D'Silva - 21 Aug 2025 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Role
Chief Business Officer
Signature
/s/ Marion Odence-Ford, by Power of Attorney
Issuer symbol
OPRX
Transactions as of
21 Aug 2025
Net transactions value
$0
Form type
4
Filing time
07 Oct 2025, 11:26:07 UTC
Next filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
D'Silva Andrew J. Chief Business Officer C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM /s/ Marion Odence-Ford, by Power of Attorney 06 Oct 2025 0002083717

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPRX Common Stock Award $0 +10,417 +28% $0.000000 47,514 21 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPRX Stock Option Award $0 +23,437 $0.000000 23,437 21 Aug 2025 Common Stock 23,437 $16.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 21, 2026, which is the first anniversary of the grant date.
F2 The stock option vests in three equal annual installments beginning August 21, 2026, the first anniversary of the grant date.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.